Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL Meeting Abstract


Authors: Park, J. H.; Lee, J. O.; Stone, R. M.; Saven, A.; Altman, J. K.; Grever, M. R.; Rai, K. R.; Vemuri, S.; Abdel-Wahab, O. I.; Tallman, M. S.
Abstract Title: Acquired resistance to BRAF inhibition in HCL is rare and retreatment with vemurafenib at relapse can induce high response rates: Final results of a phase II trial of vemurafenib in relapsed HCL
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837601101
PROVIDER: wos
Notes: Meeting Abstract: 392 -- Source: Wos